SAVA - NASDAQ
Cassava Sciences, Inc.
$1.96
-6.5%Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
At a Glance
Live SnapshotNo Revenue Data
SAVA has not reported any revenue values in the available annual periods.
Cassava Sciences, Inc. Profit Bridge
Profitability Analysis
Cassava Sciences, Inc. Income Statement
SAVA • NASDAQ
| Cassava Sciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 41.1M | 10.9M | 11.5M | 16.8M | 20.6M | 63.7M | 66M | 53.9M | |
GROSS PROFIT | ||||||||||||||||||||
(0.0) | (0.0) | (89.4M) | (68M) | (0.0) | (3.1M) | (58K) | (69K) | (68K) | (58K) | (45K) | (7.3K) | (4.9K) | (7.6K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | -89.4M | -68M | 0.0 | -3.1M | -58K | -69K | -68K | -58K | -45K | -7.3K | 41.1M | 10.9M | 11.5M | 16.8M | 20.6M | 63.7M | 66M | 53.9M | |
OPERATING INCOME | ||||||||||||||||||||
(95.4M) | (141.4M) | (16.5M) | (12M) | (32.9M) | (3.4M) | (5M) | (6.7M) | (11.9M) | (15M) | (14.2M) | (12.4M) | (9.8M) | (14.8M) | (15M) | (30.5M) | (27.3M) | (55M) | (55.8M) | (54.5M) | |
(68.8M) | (71.8M) | (16.5M) | (12M) | (8.1M) | (3.7M) | (3.4M) | (3.7M) | (4.3M) | (5.8M) | (5.1M) | (5.1M) | (4.8M) | (7.2M) | (6.7M) | (14.8M) | (6.3M) | (9.2M) | (8.1M) | (7.7M) | |
(26.6M) | (69.6M) | (89.4M) | (68.9M) | (24.8M) | (7.3M) | (1.6M) | (3M) | (7.6M) | (9.2M) | (9.1M) | (7.3M) | (4.9M) | (7.6M) | (8.3M) | (15.7M) | (21.1M) | (45.8M) | (47.7M) | (46.8M) | |
0.0 | -141.4M | -106M | -80M | -32.9M | -6.4M | -5M | -6.7M | -11.9M | -15M | -14.2M | -12.4M | 31.4M | -3.9M | -3.5M | -13.7M | -6.8M | 8.7M | 10.2M | -553K | |
PRE-TAX INCOME | ||||||||||||||||||||
0.0 | 8.5M | 7.8M | 2.8M | 49K | 112K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 106K | 451K | 901K | 1.7M | 1.8M | 6M | 0.0 | 0.0 | |
(0.0) | (0.0) | -89.4M | -68.9M | (0.0) | -7.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 117.1M | 8.7M | 3.8M | 483K | 112K | 328K | 105K | 38K | 107K | 57K | 47K | 106K | 451K | 901K | 1.7M | 1.8M | 6M | 10.1M | 9.7M | |
-91M | -24.3M | -97.2M | -76.2M | -32.4M | -6.3M | -4.6M | -6.6M | -11.9M | -14.9M | -14.1M | -12.4M | 31.5M | -3.4M | -2.6M | -12M | -5M | 14.7M | 20.3M | 9.1M | |
NET INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -386K | (0.0) | -38K | -107K | -57K | -47K | -73K | (0.0) | (0.0) | (0.0) | -1.5M | -617K | (0.0) | (2.9M) | |
-91M | -24.3M | -97.2M | -76.2M | -32.4M | -6.3M | -4.2M | -6.6M | -11.9M | -14.9M | -14.1M | -12.4M | 31.5M | -3.4M | -2.6M | -12M | -3.5M | 15.3M | 20.3M | 6.2M |
SEC Filings
SAVA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 19, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | December 22, 2025 | October 21, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 03, 2025 | November 26, 2025 | 2025 | |
S-3 S-3 N/A | November 13, 2025 | November 13, 2025 |
Related Guides
Continue your SAVA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.